GENETIC DIVERSITY OF HEPATITIS C VIRUS IN NANAIAN REGION, KHABAROVSK TERRITORY

Examining hepatitis C virus (HCV) genetic diversity is of great practical value in molecular-epidemiological research, development of specific prevention tools and outlining therapeutic strategy. Aim of study: to conduct analysis assessing HCV genetic diversity circulating in the Nanaisky region population of the Khabarovsk territory. Materials and Methods. Molecular and genetic analysis of 124 blood plasma samples collected from patients with chronic hepatitis C and residing in the Nanaisky region was conducted. Results. HCV RNA was detected in 84 (67.7±4.2%) plasma samples. HCV genotyping was performed by using AmpliSens – 1/2/3 kit (Central Research Institute of Epidemiology, Moscow, Russian Federation) showing that genotype 3 dominated reaching up to 47.6±5.4% (n=40). Genotype 1 was detected in 30 patients (35.7±5.2%). In thirteen cases (15.5±3.9%) genotype 2 was identified, whereas in one case (1.2±1.2%) virus genotype was unidentified. Phylogenetic analysis of the nucleotide sequences in HCV NS5B region was performed for 60 HCV RNA-positive samples showing subtype ratio as follows: 1a - 2 (3.3±2.3%), 1b - 23 (38.3±6.3%), 2а – 6 (10.0±3.9%), 2с – 2 (3.3±2.3%), 3а – 27(45.0±6.4%). Three samples of RF2k/1b recombinant virus were found. A full NS2 gene nucleotide sequence was cloned in order to confirm the recombination event. The results of the study evidence about a need to conduct multi-layered examination of patients with chronic hepatitis C by using current molecular and biologic methods for assigning proper therapy coupled to characteristics of the isolated strains. The data regarding hepatitis C virus molecular and genetic parameters circulating in the Far Eastern Federal District, Russia, are rather limited. Hence, our study would contribute to current understanding of HCV genovariants circulating in territories of the Russian Federation.

Download Full-text

CLINICAL PROFILE AND THE CIRCULATING GENOTYPES OF HEPATITIS C VIRUS IN A TERTIARY CARE HOSPITAL IN WEST BENGAL

10.36106/gjra/6811683 ◽

2021 ◽

pp. 165-167

Author(s):

Kumkum Sarkar ◽

Rupak Chatterjee ◽

Sumanta Sinha ◽

Netai Pramanik

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Tertiary Care Hospital ◽

Tertiary Care ◽

Hcv Rna ◽

Care Hospital ◽

Patient Department

Background and objectives- Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with majority of the patients being asymptomatic and when they present to clinicians, they have already advanced liver disease in form of cirrhosis or hepatocellular carcinoma. Data from developing countries on this evolving global health problem are sparse. Hence this study was planned with the aim to determine the HCV genotypes prevalant in patients attending a tertiary care hospital with their clinical prole. Materials and Methods- Detailed history taking and clinical examination were done of consecutive 30 patients who attended out-patient department or admitted at in- patient department of Tropical Medicine with chronic hepatitis C. Laboratory investigations like LFT, viral serology (HBsAg, AntiHCV, HIV), prothrombin time, ultrasonography of upper abdomen, HCV- RNA Quantative assay with genotyping were done. Data were collected and then analysed using standard statistical methods. Result- Of proposed 30 sample size, complete data could be collected of 28 patients and accordingly, analysis was done. Of the 28 HCV seroreactive individuals, majority (20) were males. The mode of transmission was unknown in 19 patients, blood transfusion in 5 patients who were thalassemic and hemodialysis in remaining 4 patients. Most of the patients (18/28) were asymptomatic even if their viral load was high. Most common presenting symptom was dyspepsia. LFT showed signicant transaminitis in 50% of the patients. Of the 28 seroreactive patients, 15 (53.57%) were HCV RNA positive based on RT-PCR. HCV rNA was below detectable level in 13 patients. HCV genotype 3 was the predominant genotype found in 11 individuals followed by genotype 1 found in 3 and genotype 2 was seen in one individual. Conclusion- Community screening specially among high risk individuals is needed for early diagnosis and prompt treatment of chronic hepatitis C to prevent its several complications and also to prevent community spread.

Download Full-text

Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response

Liver International ◽

10.1111/j.1478-3231.2008.01736.x ◽

2009 ◽

Vol 29 (1) ◽

pp. 120-125 ◽

Cited By ~ 8

Author(s):

Hidenori Toyoda ◽

Takashi Kumada ◽

Seiki Kiriyama ◽

Yasuhiro Sone ◽

Makoto Tanikawa ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Virological Response ◽

Rapid Virological Response ◽

Virus Genotype ◽

Genotype 2 ◽

Peginterferon And Ribavirin

Download Full-text

Distribution of hepatitis C virus genotypes and subtypes in a group of patients with chronic hepatitis C from Canton Sarajevo, 2012-2018

Acta Medica Saliniana ◽

10.5457/ams.v49i0.524 ◽

2019 ◽

Vol 49 ◽

Author(s):

Irma Salimović- Bešić ◽

Adna Kahriman ◽

Suzana Arapčić ◽

Amela Dedeić- Ljubović

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Hcv Rna ◽

Genotype 3 ◽

Hcv Genotype ◽

Hcv Genotypes ◽

Number Of Patients ◽

Subtype 1B

Background: Hepatitis C virus (HCV) genotypes and subtypes exhibit significant geographic variations.Aim: To analyse the distribution of genotypes/subtypes of HCV in a group of patients with chronic hepatitis C from Canton Sarajevo during 2012-2018.Material and methods:The study enrolled 247 human plasma samples of HCV-RNA positive patients with available results of HCV genotyping test.Results: During 2012-2018, the domination of subtypes 1a (34.01%), 1b (28.34%) and genotype 3 (23.89%) was registered. In 2012 and 2013, HCV subtype 1a was the most common (27/63; 42.86% and 17/40; 42.50%, respectively). In 2014, the leading HCV genotype/subtype were 3 and 1b (17/57; 29.82%). In 2015, the dominance of HCV genotype 3 (14/39; 35.90%) continued, while in 2016, the same number of HCV subtypes 1a and 1b (11/30; 36.67%) was recorded. Although in a small number of tested, during 2017, HCV subtype 1b was the most prevalent (7/14; 50.00%), and in 2018, it was replaced by a HCV subtype 1a (3/4; 75.00%). Distribution of HCV genotypes/subtypes by age group of patients varied significantly (p=0.000). The largest number of patients (71/247; 28.74%) belonged to the age category 30-39 years and HCV genotypes/subtypes 1, 3, 4, 1a and 1b were identified. Except in 2017, male gender significantly dominated (p=0.000). In males, HCV subtype 1a (68/170; 40.00%) was the most common, while in women it was HCV subtype 1b (44/77; 57.14%).Conclusion: This six-year retrospective study showed the time variations of the circulating HCV genotypes/subtypes among patients with chronic hepatitis C in Canton Sarajevo. Genotyping of the HCV has an important implications for diagnosis and treatment of the patients.

Download Full-text

Chronic hepatitis C virus infections in Brazilian patients: association with genotypes, clinical parameters and response to long term alpha interferon therapy

Revista do Instituto de Medicina Tropical de São Paulo ◽

10.1590/s0036-46651999000300010 ◽

1999 ◽

Vol 41 (3) ◽

pp. 183-189 ◽

Cited By ~ 3

Author(s):

Leda BASSIT ◽

Luiz C. DA SILVA ◽

Gabriela RIBEIRO-DOS-SANTOS ◽

Geert MAERTENS ◽

Flair J. CARRILHO ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Hcv Infection ◽

Sustained Response ◽

Response To Treatment ◽

Recombinant Interferon ◽

Genotype 2

The present study assessed the clinical significance of hepatitis C virus (HCV) genotypes and their influence on response to long term recombinant-interferon-alpha (r-IFN-a) therapy in Brazilian patients. One hundred and thirty samples from patients previously genotyped for the HCV and with histologically confirmed chronic hepatitis C (CH-C) were evaluated for clinical and epidemiological parameters (sex, age, time of HCV infection and transmission routes). No difference in disease activity, sex, age or mode and time of transmission were seen among patients infected with HCV types 1, 2 or 3. One hundred and thirteen of them were treated with 3 million units of r-IFN-a, 3 times a week for 12 months. Initial response (IR) was significantly better in patients with genotype 2 (100%) and 3 (46%) infections than in patients with genotype 1 (29%) (p < 0.005). Among subtypes, difference in IR was observed between 1b and 2 (p < 0.005), and between 1b and 3a (p < 0.05). Sustained response (SR) was observed in 12% for (sub)type 1a, 13% for 1b, 19% for 3a, and 40% for type 2; significant differences were found between 1b and 2 (p < 0.001), and between 1b and 3a (p < 0.05). Moreover, presence of cirrhosis was significantly associated with non response and response with relapse (p < 0.05). In conclusion, non-1 HCV genotype and lack of histological diagnosis of cirrhosis were the only baseline features associated with sustained response to treatment. These data indicate that HCV genotyping may have prognostic relevance in the responsiveness to r-IFN-a therapy in Brazilian patients with chronic HCV infection, as seen in other reports worldwide.

Download Full-text

Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.01521-12 ◽

2012 ◽

Vol 56 (12) ◽

pp. 6372-6378 ◽

Cited By ~ 13

Author(s):

Jacob Lalezari ◽

David Asmuth ◽

Arnaldo Casiró ◽

Hugo Vargas ◽

Shannon Lawrence ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Viral Load ◽

Hepatitis C ◽

Adverse Events ◽

Antiviral Activity ◽

Chronic Hepatitis C ◽

Hcv Rna ◽

Plasma Exposure ◽

Chronic Hepatitis C Virus

ABSTRACTIDX184 is a liver-targeted prodrug of 2′-methylguanosine (2′-MeG) monophosphate. This study investigated the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184 as a single agent in treatment-naïve patients with genotype-1 chronic hepatitis C virus (HCV) infection. Forty-one patients with baseline HCV RNA ≥ 5 log10IU/ml, alanine aminotransferase (ALT) ≤ 2.5× the upper limit of normal, and compensated liver disease were dosed. Sequential cohorts of 10 patients, randomized 8:2 (active:placebo), received 25, 50, 75, and 100 mg of IDX184 once daily for 3 days, with a 14-day follow-up. There were no safety-related treatment discontinuations or serious adverse events. The adverse events and laboratory abnormalities observed for IDX184- and placebo-treated patients were similar. At the end of the 3-day treatment period, changes from baseline in HCV RNA levels (means ± standard deviations) were −0.5 ± 0.6, −0.7 ± 0.2, −0.6 ± 0.3, and −0.7 ± 0.5 log10for the 25-, 50-, 75-, and 100-mg doses, respectively, while viral load remained unchanged for the pooled placebo patients (−0.05 ± 0.3 log10). Patients with genotype-1a and patients with genotype-1b responded similarly. Serum ALT levels decreased, especially at daily doses ≥ 75 mg. During the posttreatment period, plasma viremia and serum aminotransferase levels returned to near pretreatment levels. No resistance mutations associated with IDX184 were detected. Plasma exposure of IDX184 and its nucleoside metabolite 2′-MeG was dose related and low. Changes in plasma viral load correlated with plasma exposure of 2′-MeG. In conclusion, the results from this proof-of-concept study show that small doses of the liver-targeted prodrug IDX184 were able to deliver significant antiviral activity and support further clinical evaluation of the drug candidate.

Download Full-text